Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis

1 Nov 2024

Abstract excerpt

AIMS: Patients with glioblastoma multiforme (GBM) do not benefit from current cancer treatments, and their prognosis is dismal. This study aimed to investigate the potential synergistic effects of TS-2021, a third-generation oncolytic adenovirus, combined with the PARP inhibitor olaparib in GBM. METHODS: TS-2021's impact on p66shc-induced apoptosis, DNA damage response, and poly (ADP-ribose) polymerase (PARP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Sirtuins and Resveratrol in Medicine
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39552450
DOI: 10.1111/cns.70124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced ApoptosisPMID 39552450Read ↗

Rad51 Degradation: Role in Oncolytic Virus—Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in GlioblastomaSemantic proximity Read ↗

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsSemantic proximity Read ↗

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.Semantic proximity Read ↗

Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screeningSemantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in GlioblastomaSemantic proximity Read ↗

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Semantic proximity Read ↗

Towards an armed oncolytic virus approach to glioblastoma treatmentSemantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerationsSemantic proximity Read ↗

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft ModelsSemantic proximity Read ↗

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.